How Is Severe Tricuspid Regurgitation Treated?

Severe tricuspid regurgitation—a condition in which the tricuspid valve fails to close properly, allowing significant backflow of blood from the right ventricle into the right atrium—requires prompt and individualized management. Left untreated, it can lead to progressive right heart failure, systemic venous congestion, hepatic dysfunction, ascites, and reduced exercise tolerance.

Initial evaluation centers on echocardiography—particularly transthoracic and, when needed, transesophageal—to quantify regurgitant severity, assess right ventricular size and function, evaluate pulmonary artery pressures, and identify underlying causes such as functional (secondary) disease due to right ventricular dilation or left-sided heart disease, or organic (primary) pathology like infective endocarditis, carcinoid heart disease, or prior radiation exposure.

Medical therapy focuses on symptom control and addressing contributing factors: diuretics (e.g., furosemide, spironolactone) to relieve volume overload and peripheral edema; optimization of left-sided heart failure if present; and treatment of pulmonary hypertension when indicated. However, pharmacologic interventions do not reverse valve dysfunction or halt disease progression.

Surgical intervention remains the cornerstone for eligible patients with severe, symptomatic tricuspid regurgitation—especially those undergoing concurrent left-sided valve surgery. Options include tricuspid annuloplasty (the preferred approach for functional disease), valve repair with adjunctive techniques (e.g., edge-to-edge repair), or, less commonly, tricuspid valve replacement using mechanical or bioprosthetic prostheses. Patient selection hinges on surgical risk, right ventricular reserve, and likelihood of durable benefit.

For high-risk or inoperable patients, transcatheter therapies are emerging as viable alternatives. These include transcatheter tricuspid valve repair (e.g., edge-to-edge clipping via systems like the PASCAL or TriClip devices) and investigational transcatheter valve replacement platforms. While long-term durability data remain limited, early clinical trials demonstrate meaningful reductions in regurgitation severity and improvements in functional status and quality of life.

Management decisions should be made within a multidisciplinary heart valve team—including cardiologists, cardiac surgeons, imaging specialists, and heart failure experts—to ensure alignment with patient goals, comorbidities, and procedural risk profiles.